Cite
45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial.
MLA
Chan, A., et al. “45P Long-Term Efficacy of Neratinib in HER2-Positive Early-Stage Breast Cancer: Overall Survival and Central Nervous System Outcomes from the Phase III ExteNET Trial.” Annals of Oncology, vol. 32, May 2021, p. S40. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.03.059.
APA
Chan, A., Moy, B., Mansi, J. L., Gnant, M. I., Barrios, C. H., Separovic, R., Guerrero-Zotano, A., Gore, I., Smith, J., Bryce, R. P., Xu, F., Wong, A., Martin, M., & Holmes, F. A. (2021). 45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial. Annals of Oncology, 32, S40. https://doi.org/10.1016/j.annonc.2021.03.059
Chicago
Chan, A., B. Moy, J.L. Mansi, M.I. Gnant, C.H. Barrios, R. Separovic, A. Guerrero-Zotano, et al. 2021. “45P Long-Term Efficacy of Neratinib in HER2-Positive Early-Stage Breast Cancer: Overall Survival and Central Nervous System Outcomes from the Phase III ExteNET Trial.” Annals of Oncology 32 (May): S40. doi:10.1016/j.annonc.2021.03.059.